Glenmark Laboratories Pvt Ltd, a biopharmaceutical player is looking at developing and marketing recombinant biotechnology products in
India. At present it is sourcing the products from licensors.
Commenting on future plans, Mark Saldanha, managing director, Glenmark Laboratories said, "We will not limit ourselves to sourcing products from licensors but also develop and market them in India. We have plans to set up fermentation facilities for manufacturing recombinant proteins and other biologics. These facilities will be in place in the next two years."
The company recently announced an integrated alignment pact with TASC Pharmaceuticals Ltd. "The amalgamated entity has given a revenue guidance of Rs 590 crore for FY 2006. The growth in FY2006 for combined entity is expected to come from the C-R-A-M-S contracts in hand, biopharmaceuticals and R&D-based services in additions to benefits from wider product basket and market penetration, " said Mark Saldanha.